Bukwang Pharm signs exclusive sales agreement of schizophrenia treatment ‘lurasidone’

Bukwang Pharm announced it signed an exclusive license agreement od development, marketing, sales and distribution in Korea for ‘lurasidone’ developed by Sumitomo Dainippon Pharma for the indication of schizophrenia and bipolar disorder.

Lurasidone, an atypical schizophrenia treatment, works as an antagonist which blocks dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors. It shows par...